Management of Acute Exacerbations of Chronic Obstructive Pulmonary Disease in the Elderly

Global Initiative for Chronic Obstructive Lung Disease. Workshop report: global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease, updated November 2006 [online]. Available from URL: http://www.goldcopd.com [Accessed 2007 Mar 12] Mackay J, Eriksen M. The tobacco atlas. Geneva: World Health Organization, 2002 Sezer H, Akkurt I, Guler N, et al. A case-control study on the effect of exposure to different substances on the development of COPD. Ann Epidemiol 2006; 16: 59–62 Ekici A, Ekici M, Kurtipek E, et al. Obstructive airway diseases in women exposed to biomass smoke. Environ Res 2005; 99: 93–8 Kiraz K, Kart L, Demir R, et al. Chronic pulmonary disease in rural women exposed to biomass fumes. Clin Invest Med 2003; 26: 243–8 Bakke S, Baste V, Hanoa R, et al. Prevalence of obstructive lung disease in a general population: relation to occupational title and exposure to some airborne agents. Thorax 1991; 46: 863–70 Murray CJL, Lopez AD. Alternative projections of mortality and disability by cause 1990–2020: Global Burden of Disease Study. Lancet 1997; 349: 1498–504 National Heart, Lung, and Blood Institute. Morbidity and mortality: 2002 chartbook on cardiovascular, lung, and blood diseases. Bethesda (MD): US Department of Health and Human Services, NIH, NHLBI, 2004 May [online]. Available from URL: http://www.nhlbi.nih.gov/resources/docs/04_chtbk.pdf [Accessed 2007 Feb 27] Holguin F, Folch E, Redd SC, et al. Comorbidity and mortality in COPD-related hospitalizations in the United States, 1979 to 2001. Chest 2005; 128: 2005–11 Anthonisen NR, Manfreda J, Warren CP, et al. Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. Ann Intern Med 1987; 106: 196–204 Rodriguez-Roisin R. Toward a consensus definition for COPD exacerbations. Chest 2000; 117 (5 Suppl. 2): 398S–401S Niewoehner DE, Collins D, Erbland ML. Relation of FEV1 to clinical outcomes during exacerbations of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2000; 161: 1201–5 Seemungal TA, Donaldson GC, Bhowmik A, et al. Time course and recovery of exacerbations in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2000; 161: 1608–13 Hurst JR, Donaldson GC, Perera WR, et al. Use of plasma biomarkers at exacerbation of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2006; 174: 867–74 Miravitlles M, Ferrer M, Pont A, et al. Effect of exacerbations on quality of life in patients with chronic obstructive pulmonary disease: a 2 year follow up study. Thorax 2004; 59: 387–95 Parker CM, Voduc N, Aaron SD, et al. Physiological changes during symptom recovery from moderate exacerbations of COPD. Eur Respir J 2005; 26: 420–8 Davies L, Angus RM, Calverley PM. Oral corticosteroids in patients admitted to hospital with exacerbations of chronic obstructive pulmonary disease: a prospective randomised controlled trial. Lancet 1999; 354: 456–60 Niewoehner DE, Erbland ML, Deupree RH, et al. Effect of systemic glucocorticoids on exacerbations of chronic obstructive pulmonary disease. Department of Veterans Affairs Cooperative Study Group. N Engl J Med 1999; 340: 1941–7 Patil SP, Krishnan JA, Lechtzin N, et al. In-hospital mortality following acute exacerbations of chronic obstructive pulmonary disease. Arch Intern Med 2003; 163: 1180–6 Cydullka RK, McFadden ER Jr, Emerman CL, et al. Patterns of hospitalization in elderly patients with asthma and chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1997; 156: 1807–12 Seneff MG, Wagner DP, Wagner RP, et al. Hospital and 1-year survival of patients admitted to intensive care units with acute exacerbation of chronic obstructive pulmonary disease. JAMA 1995; 274: 1852–7 Connors AF Jr, Dawson NV, Thomas C, et al. Outcomes following acute exacerbation of severe chronic obstructive lung disease: the SUPPORT investigators (Study to Understand Prognoses and Preferences for Outcomes and Risks of Treatments). Am J Respir Crit Care Med 1996; 154: 959–67 Sin DD, Tu JV. Inhaled corticosteroids and the risk of mortality and readmission in elderly patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001; 164: 580–4 Groenewegen KH, Schols AM, Wouters EF. Mortality and mortality-related factors after hospitalization for acute exacerbation of COPD. Chest 2003; 124: 459–67 Spencer S, Jones PW, GLOBE Study Group. Time course of recovery of health status following an infective exacerbation of chronic bronchitis. Thorax 2003; 58: 589–93 Spencer S, Calverley PM, Burge PS, et al. Impact of preventing exacerbations on deterioration of health status in COPD. Eur Respir J 2004; 23: 698–702 Donaldson GC, Seemungal TA, Bhowmik A, et al. Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease. Thorax 2002; 57: 847–52 Fagon JY, Chastre J, Trouillet JL, et al. Characterization of distal bronchial microflora during acute exacerbation of chronic bronchitis. Am Rev Respir Dis 1990; 142: 1004–8 Soler N, Torres A, Ewig S, et al. Bronchial microbial patterns in severe exacerbations of chronic obstructive pulmonary disease(COPD) requiring mechanical ventilation. Am J Respir Crit Care Med 1998; 157: 1498–505 Pela R, Marchesani FF, Agostinelli C, et al. Airways microbial flora in COPD patients in stable clinical conditions and during exacerbations: a bronchoscopic investigation. Monaldi Arch Chest Dis 1998; 53: 262–7 Monso E, Ruiz J, Rosell A, et al. Bacterial infection in chronic obstructive pulmonary disease: a study of stable and exacerbated outpatients using the protected specimen brush. Am J Respir Crit Care Med 1995; 152: 1316–20 Sethi S, Evans N, Grant BJB, et al. New strains of bacteria and exacerbations of chronic obstructive pulmonary disease. N Engl J Med 2002; 347: 465–71 Sethi S, Wrona C, Grant BJB, et al. Strain-specific immune responses to Haemophilus influenzae in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2004; 169: 448–53 Beckham JB, Cadena A, Lin J, et al. Respiratory viral infections in patients with chronic obstructive pulmonary disease. J Infect 2005; 50: 322–30 Rohde G, Wiethege A, Borg I, et al. Respiratory viruses in exacerbations of chronic obstructive pulmonary disease requiring hospitalisation: a case-control study. Thorax 2003; 58: 37–42 Blasi F, Legnani D, Lombardo VM, et al. Chlamydia pneumoniae infection in acute exacerbations of COPD. Eur Respir J 1993; 6: 19–22 Beaty CD, Grayston JT, Wang SP, et al. Chlamydia pneumoniae, strain TWAR, infection in patients with chronic obstructive pulmonary disease. Am Rev Respir Dis 1991; 144: 1408–10 Lieberman D, Lieberman D, Ben-Yaakov M, et al. Serological evidence of Mycoplasma pneumoniae infection in acute exacerbation of COPD. Diagn Microbiol Infect Dis 2002; 44: 1–6 MacNee W, Donaldson K. Exacerbations of COPD: environmental mechanisms. Chest 2000; 117 (5 Suppl. 2): 390S–7S Sunyer J, Saez M, Murillo C, et al. Air pollution and emergency room admissions for chronic obstructive pulmonary disease: a 5-year study. Am J Epidemiol 1993; 137: 701–5 Mannino DM, Homa DM, Akinbami LJ, et al. Chronic obstructive pulmonary disease surveillance — United States, 1971–2000. MMWR Surveill Summ 2002; 51(SS6): 1–16 National Center for Health Statistics. The National Health Interview Survey (NHIS), 1988–1994. Hyattsville (MD): Division of Health Interview Statistics, National Center for Health Statistics, Centers for Disease Control and Prevention [online]. Available from URL: http://www.cdc.gov/nchs/nhis.htm [Accessed 2006 Feb 27] National Center for Health Statistics. The Third National Health and Nutrition Examination Survey (NHANES III), 1988–94. Hyattsville (MD): National Center for Health Statistics, Centers for Disease Control and Prevention [online]. Available from URL: http://www.cdc.gov/nchs/about/major/nhanes/nh3data.htm [Accessed 2006 Feb 27] Anthonisen NR. Prognosis in chronic obstructive pulmonary disease: results from multicenter clinical trials. Am Rev Respir Dis 1989; 140: S95–9 Miravitlles M, Guerrero T, Mayordomo C, et al. Factors associated with increased risk of exacerbation and hospital admission in a cohort of ambulatory COPD patients: a multiple logistic regression analysis. Respiration 2000; 67: 495–501 Roberts CM, Lowe D, Bucknall CE, et al. Clinical audit indicators of outcome following admission to hospital with acute exacerbation of chronic obstructive pulmonary disease. Thorax 2002; 57: 137–41 Kessler R, Faller M, Fourgaut G, et al. Predictive factors of hospitalization for acute exacerbation in a series of 64 patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1999; 159: 158–64 Seemungal TAR, Donaldson GC, Paul EA, et al. Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1998; 157: 1418–22 Osman LM, Godden DJ, Friend JAR, et al. Quality of life and hospital re-admission in patients with chronic obstructive pulmonary disease. Thorax 1997; 52: 67–71 Niewoehner DE, Lokhnygina Y, Rice K, et al. Risk indices for exacerbations and hospitalizations due to COPD. Chest 2007; 131: 20–28 Warren PM, Flenley DC, Millar JS, et al. Respiratory failure revisited: acute exacerbations of chronic bronchitis between 1961–68 and 1970–76. Lancet 1980; 1(8166): 467–70 Heuser MD, Case LD, Ettinger WH. Mortality in intensive care patients with respiratory disease: is age important? Arch Intern Med 1992; 152: 1683–8 Fuso L, Incalzi RA, Pistelli R, et al. Predicting mortality of patients hospitalized for acutely exacerbated chronic obstructive pulmonary disease. Am J Med 1995; 98: 272–7 Svartengren M, Falk R, Philipson K. Long-term clearance from small airways decreases with age. Eur Respir J 2005; 26: 609–15 Kikawada M, Iwamoto T, Takasaki M. Aspiration and infection in the elderly: epidemiology, diagnosis, and management. Drugs Aging 2005; 22: 115–30 Meyer KC. Aging. Proc Am Thorac Soc 2005; 2: 433–9 American Thoracic Society and European Respiratory Society standards for the diagnosis and management of patients with COPD. American Thoracic Society [online]. Available from URL: http://www.thoracic.org/sections/copd/index.html [Accessed 2007 Mar 12] Proskocil BJ, Fryer AD. Beta2-agonist and anticholinergic drugs in the treatment of lung disease. Proc Am Thorac Soc 2005; 2: 305–10 Belmonte KE. Cholinergic pathways in the lungs and anticholinergic therapy for chronic obstructive pulmonary disease. Proc Am Thorac Soc 2005; 2: 297–304 Backman R, Hellstrom P. Fenoterol and ipratropium bromide for treatment of patients with chronic bronchitis. Curr Ther Res 1985; 38: 135–40 Rebuck AS, Chapman KR, Abboud R, et al. Nebulized anticholinergic and sympathomimetic treatment of asthma and chronic obstructive pulmonary disease in the emergency room. Am J Med 1987; 82: 59–64 Karpel JP, Pesin J, Greenberg D, et al. A comparison of the effects of ipratropium bromide and metaproterenol sulfate in acute exacerbations of COPD. Chest 1990; 98: 835–9 COMBIVENT Inhalation Solution Study Group. Routine nebulized ipratropium and albuterol together are better then either alone in COPD. Chest 1997; 112: 1514–21 Gross N, Tashkin D, Miller R, et al. Inhalation by nebulization of albuterol-ipratropium combination (Dey combination) is superior to either agent alone in the treatment of chronic obstructive pulmonary disease. Dey Combination Solution Study Group. Respiration 1998; 65: 354–62 O’Driscoll BR, Taylor RJ, Horsley MG, et al. Nebulized salbutamol with and without ipratropium bromide in acute airflow obstruction. Lancet 1989; 1: 1418–20 Moayyedi P, Congleton J, Page RL, et al. Comparison of nebulized salbutamol and ipratropium bromide with salbutamol alone in the treatment of chronic obstructive pulmonary disease. Thorax 1995; 50: 834–7 Patrick DM, Dales RE, Stark RM, et al. Severe exacerbations of COPD and asthma: incremental benefit of adding ipratropium to usual therapy. Chest 1990; 98: 295–7 Shrestha M, O’Brien T, Haddox R, et al. Decreased duration of emergency department treatment of chronic obstructive pulmonary disease exacerbations with the addition of ipratropium bromide to beta-agonist therapy. Ann Emerg Med 1991; 20: 1206–9 Berry RB, Shinto RA, Wong FH, et al. Nebulizer vs. spacer for bronchodilator therapy in patients hospitalized for acute exacerbations of COPD. Chest 1989; 96: 1241–6 Greene AB Jr, Jackson CL. Terbutaline metered-dose inhalation vs. metaproterenol by hand-held nebulization: a comparison in black inner-city COPD patients. J Natl Med Assoc 1988; 80: 393–6 Higgins RM, Cookson WO, Chadwick GA. Changes in blood gas levels after nebuhaler and nebulizer administration of terbutaline in severe chronic airway obstruction. Bull Eur Physiopathol Respir 1987; 23: 261–4 Jasper AC, Mohsenifar Z, Kahan S, et al. Cost-benefit comparison of aerosol bronchodilator delivery methods in hospitalized patients. Chest 1987; 91: 614–8 Maguire GP, Newman T, DeLorenzo LJ, et al. Comparison of a hand-held nebulizer with a metered-dose inhaler-spacer combination in acute obstructive pulmonary disease. Chest 1991; 100: 1300–5 Summer W, Elston R, Tharpe L, et al. Aerosol bronchodilator delivery methods: relative impact on pulmonary function and cost of respiratory care. Arch Intern Med 1989; 149: 618–23 Turner JR, Corkery KJ, Eckman D, et al. Equivalence of continuous flow nebulizer and metered-dose inhaler with reservoir bag for treatment of acute airflow obstruction. Chest 1988; 93: 476–81 Armitage JM, Williams SJ. Inhaler technique in the elderly. Age Ageing 1988; 17: 275–8 Connolly MJ. Inhaler technique of elderly patients: comparison of metered-dose inhalers and large volume spacer devices. Age Ageing 1995; 24: 190–2 Connolly MJ, Crowley JJ, Charan NB, et al. Impaired bronchodilator response to albuterol in healthy elderly men and women. Chest 1995; 108: 401–6 Barros MJ, Rees PJ. Bronchodilator responses to salbutamol followed by ipratropium bromide in partially reversible airflow obstruction. Respir Med 1990; 84: 371–5 Lipworth BJ, Tregaskis BF, McDevitt DG. Comparison of hypokalemic, electrocardiographic and hemodynamic responses to inhaled isoprenaline and salbutamol in young and elderly subjects. Eur J Clin Pharmacol 1991; 40: 255–60 Mandelberg A, Krupnik Z, Houri S, et al. Salbutamol metereddose inhaler with spacer for hyperkalemia: how fast? How safe? Chest 1999; 115: 617–22 Breeden CC, Safirstein BH. Albuterol and spacer-induced atrial fibrillation. Chest 1990; 98: 762–3 Bouvy ML, Heerdink ER, DeBruin ML, et al. Use of sympathomimetic drugs leads to increased risk of hospitalization for arrhythmias in patients with congestive heart failure. Arch Intern Med 2000; 160: 2477–80 Anthonisen NR, Connett JE, Enright PL, et al. Hospitalizations and mortality in the Lung Health Study. Am J Respir Crit Care Med 2002; 166: 333–9 Pakes GE, Brogden RN, Heel RC, et al. Ipratropium bromide: a review of its pharmacological properties and therapeutic efficacy in asthma and chronic bronchitis. Drugs 1980; 20: 237–66 Chapman KR, Smith DL, Rebuck AS, et al. Hemodynamic effects of inhaled ipratropium bromide alone and combined with an inhaled beta2-agonist. Am Rev Respir Dis 1985; 132: 845–7 Pras E, Stienlauf S, Pinkhas J, et al. Urinary retention associated with ipratropium bromide. DICP 1991; 25: 939–40 Hall SK. Acute angle-closure glaucoma as a complication of combined beta-agonist and ipratropium bromide therapy in the emergency department. Ann Emerg Med 1994; 23: 884–7 Handley D. The asthma-like pharmacology and toxicology of (S)-isomers of beta agonists. J Allergy Clin Immunol 1999; 104: S69–76 Datta D, Vitale A, Lahiri B, et al. An evaluation of nebulized levalbuterol in stable COPD. Chest 2003; 124: 844–9 Nowak R, Emerman C, Hanrahan JP, et al. A comparison of levalbuterol with racemic albuterol in the treatment of acute severe asthma exacerbations in adults. Am J Emerg Med 2006; 24: 259–67 Scott VL, Frazee LA. Retrospective comparison of nebulized levalbuterol and albuterol for adverse events in patients with acute airflow obstruction. Am J Ther 2003; 10: 341–7 Lam S, Chen J. Changes in heart rate associated with nebulized racemic albuterol and levalbuterol in intensive care patients. Am J Health Syst Pharm 2003; 19: 1971–5 Truitt T, Witko J, Halpern M. Levalbuterol compared to racemic albuterol: efficacy and outcomes in patients hospitalized with COPD or asthma. Chest 2003; 123: 128–35 Cosio BG, Tsaprouni L, Ito K, et al. Theophylline restores histone deacetylase activity and steroid responsiveness in COPD macrophages. J Exp Med 2004; 200: 689–95 Kongragunta VR, Druz WS, Sharp JT. Dyspnea and diaphragmatic fatigue in patients with chronic obstructive pulmonary disease: responses to theophylline. Am Rev Respir Dis 1988; 137: 662–7 Umut S, Gemicioglu B, Yildirim N, et al. Effect of theophylline in chronic obstructive lung disease. Int J Clin Pharmacol Ther Toxicol 1992; 30: 149–52 Wrenn K, Slovis CM, Murphy F, et al. Aminophylline therapy for acute bronchospastic disease in the emergency room. Ann Intern Med 1991; 115: 241–7 Rice KL, Leatherman JW, Duane PG, et al. Aminophylline for acute exacerbation of chronic obstructive pulmonary disease: a controlled trial. Ann Intern Med 1987; 107: 305–9 Seidenfeld JJ, Jones WN, Moss RE, et al. Intravenous aminophylline in the treatment of acute bronchospastic exacerbations of chronic obstructive pulmonary disease. Ann Emerg Med 1984; 13: 248–52 Duffy N, Walker P, Diamantea F, et al. Intravenous aminophylline in patients admitted to hospital with non-acidotic exacerbations of chronic obstructive pulmonary disease: a prospective randomised controlled trial. Thorax 2005; 60: 713–7 Emerman CL, Devlin C, Connors AF. Risk of toxicity in patients with elevated theophylline levels. Ann Emerg Med 1990; 19: 643–8 Armijo JA, Sanchez BM, Peralta FG, et al. Pharmacokinetics of an ultralong sustained-release theophylline formulation when given twice daily in elderly patients with chronic obstructive pulmonary disease: monitoring implications. Biopharm Drug Dispos 2003; 24: 165–71 Ohnishi A, Kato M, Kojima J, et al. Differential pharmacokinetics of theophylline in elderly patients. Drugs Aging 2003; 20: 71–84 Barr RG, Rowe BH, Camargo CA. Methylxanthines for exacerbations of chronic obstructive pulmonary disease: a meta-analysis of randomised trials. BMJ 2003; 327: 643–8 Albert RK, Martin TR, Lewis SW. Controlled clinical trial of methylprednisolone in patients with chronic bronchitis and acute respiratory insufficiency. Ann Intern Med 1980; 92: 753–8 Maltais F, Ostinelli J, Bourbeau J, et al. Comparison of nebulized budesonide and oral prednisolone with placebo in the treatment of acute exacerbations of chronic obstructive pulmonary disease: a randomized controlled trial. Am J Respir Crit Care Med 2002; 165: 698–703 Thompson WH, Nielson CP, Carvalho P, et al. Controlled trial of oral prednisone in outpatients with acute COPD exacerbation. Am J Respir Crit Care Med 1996; 154: 407–12 Aaron SD, Vandemheen KL, Hebert P, et al. Outpatient oral prednisone after emergency treatment of chronic obstructive pulmonary disease. N Engl J Med 2003; 348: 2618–25 Sayiner A, Aytemur ZA, Cirit M, et al. Systemic corticosteroids in severe exacerbations of COPD. Chest 2001; 119: 726–30 Boston Collaborative Drug Surveillance Program. Acute adverse reactions to prednisone in relation to dosage. Clin Pharmacol Ther 1972; 13: 694–8 Stuck AE, Minder CE, Frey FJ. Risk of infectious complications in patients taking glucocorticoids. Rev Infect Dis 1989; 11: 954–63 Conn HO, Poynard T. Corticosteroids and peptic ulcer: meta-analysis of adverse events during steroid therapy. J Intern Med 1994; 236: 619–32 Amaya-Villar R, Garnacho-Montero J, Garcia-Garmendia JL, et al. Steroid-induced myopathy in patients intubated due to exacerbation of chronic obstructive pulmonary disease. Intensive Care Med 2005; 31: 157–61 De Jonghe B, Sharshar T, Lefaucheur JP, et al. Paresis acquired in the intensive care unit: a prospective multicenter study. JAMA 2002; 288: 2859–67 Kumar S. Steroid-induced myopathy following a single oral dose of prednisolone. Neurol India 2003; 51: 554–6 Dekhuijzen PN, Decramer M. Steroid-induced myopathy and its significance to respiratory disease: a known disease rediscovered. Eur Respir J 1992; 5: 997–1003 Alonso Martinez JL, Rubio Obanos MT, Samperiz Legarre AL, et al. Antibiotic treatment for acute episodes of chronic obstructive pulmonary disease [in Spanish]. An Med Interna 1992; 9: 377–80 Elmes PC, King TK, Langlands JH, et al. Value of ampicillin in the hospital treatment of exacerbations of chronic bronchitis. BMJ 1965; 5467: 904–8 Hansen M, Evald T, Balslov S, et al. A randomized double-blind trial between amoxycillin and placebo in the treatment of acute exacerbations of chronic bronchitis [abstract]. Eur Resp J 1990; 3Suppl. 10: 89 Jørgensen AF, Coolidge J, Pedersen PA, et al. Amoxicillin in treatment of acute uncomplicated exacerbations of chronic bronchitis: a double-blind, placebo-controlled multicentre study in general practice. Scand J Prim Health Care 1992; 10: 7–11 Manresa F, Blavia R, Martin R, et al. Antibiotics for exacerbations of chronic bronchitis. Lancet 1987; 2: 394–5 Nicotra MB, Rivera M, Awe RJ. Antibiotic therapy of acute exacerbations of chronic bronchitis: a controlled study using tetracycline. Ann Intern Med 1982; 97: 18–21 Nouira S, Marghli S, Belghith M, et al. Once daily oral ofloxacin in chronic obstructive pulmonary disease exacerbation requiring mechanical ventilation: a randomised placebo-controlled trial. Lancet 2001; 358: 2020–5 Petersen ES, Esmann V, Honcke P, et al. A controlled study of the effect of treatment on chronic bronchitis: an evaluation using pulmonary function tests. Acta Med Scand 1967; 182: 293–305 Pines A, Raafat H, Plucinski K, et al. Antibiotic regimens in severe and acute purulent exacerbations of chronic bronchitis. BMJ 1968; 2: 735–8 Pines A, Raafat H, Greenfield JS, et al. Antibiotic regimens in moderately ill patients with purulent exacerbations of chronic bronchitis. Brit J Dis Chest 1972; 66: 107–15 Ram FSF, Rodriguez-Roisin R, Granados-Navarrete A, et al. Antibiotics for exacerbations of chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2006; 2: CD004403 Stockley RA, O’Brien C, Pye A, et al. Relationship of sputum color to nature and outpatient management of acute exacerbations of COPD. Chest 2000; 117: 1638–45 Barbera JA, Roca J, Ferrer A, et al. Mechanisms of worsening gas exchange during acute exacerbations of chronic obstructive pulmonary disease. Eur Respir J 1997; 10: 1285–91 Nocturnal Oxygen Therapy Trial Group. Continuous or nocturnal oxygen therapy in hypoxemic chronic obstructive lung disease: a clinical trial. Ann Intern Med 1980; 93: 391–8 Medical Research Council Working Party. Long term domiciliary oxygen therapy in chronic hypoxic cor pulmonale complicating chronic bronchitis and emphysema. Lancet 1981; 1: 681–6 Aubier M, Murciano D, Milic-Emili J, et al. Effects of the administration of O2 on ventilation and blood gasses in patients with chronic obstructive pulmonary disease during acute respiratory failure. Am Rev Respir Dis 1980; 122: 747–54 Dunn WF, Nelson SB, Hubmayr RD. Oxygen-induced hypercarbia in obstructive pulmonary disease. Am Rev Respir Dis 1991; 144: 526–30 Sassoon CS, Hassell KT, Mahutte CK. Hyperoxic-induced hypercapnia in stable chronic obstructive pulmonary disease. Am Rev Respir Dis 1987; 135: 907–11 Robinson TD, Frieberg DB, Regnis JA, et al. The role of hypoventilation and ventilation-perfusion redistribution in oxygen-induced hypercapnia during acute exacerbations of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2000; 161: 1524–9 Moloney ED, Kiely JL, McNicholas WT. Controlled oxygen therapy and carbon dioxide retention during exacerbations of chronic obstructive pulmonary disease. Lancet 2001; 357:526–8 Agusti AG, Carrera M, Barbe F, et al. Oxygen therapy during exacerbations of chronic obstructive pulmonary disease. Eur Respir J 1999; 14: 934–9 Plant PK, Owen JL, Elliott MW. One year period prevalence study of respiratory acidosis in acute exacerbations of COPD: implications for the provision of non-invasive ventilation and oxygen administration. Thorax 2000; 55: 550–4 Gomersall CD, Joynt GM, Freebairn RC, et al. Oxygen therapy for hypercapnic patients with chronic obstructive pulmonary disease and acute respiratory failure: a randomized, controlled pilot study. Crit Care Med 2002; 30: 113–6 Takeuchi T, Matsushima E, Moriya H, et al. Delirium in inpatients with respiratory diseases. Psychiatry Clin Neurosci 2005; 59: 253–8 Francis J, Martin D, Kapoor WN. A prospective study of delirium in hospitalized elderly. JAMA 1990; 263: 1097–101 Ram FSF, Picot J, Lighttowler J, et al. Non-invasive positive pressure ventilation for treatment of respiratory failure due to exacerbations of chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2004; 3: CD004104 Brochard L, Mancebo J, Wysocki M, et al. Noninvasive ventilation for acute exacerbations of chronic obstructive pulmonary disease. N Engl J Med 1995; 333: 817–22 Celikel T, Sungur M, Ceyhan B, et al. Comparison of noninvasive positive pressure ventilation with standard medical therapy in hypercapnic acute respiratory failure. Chest 1998; 114: 1636–42 Conti G, Antonelli M, Navalesi P, et al. Noninvasive vs. conventional mechanical ventilation in patients with chronic obstructive pulmonary disease after failure of medical treatment in the ward: a randomized trial. Intensive Care Med 2002; 28: 1701–7 Kramer N, Meyer TJ, Meharg J, et al. Randomized, prospective trial of noninvasive positive pressure ventilation in acute respiratory failure. Am J Resp Crit Care Med 1995; 151: 1799–806 Servillo G, Ughi L, Rossano F, et al. Non invasive mask pressure support ventilation in COPD patients [abstract]. Intensive Care Med 1994; 20Suppl. 2: S54 Thys F, Roeseler J, Reynaert M, et al. Noninvasive ventilation for acute respiratory failure: a prospective randomised placebo-controlled trial. Eur Respir J 2002; 20: 545–55 Avdeev SN, Tretyakov AV, Grigoryants RA, et al. Noninvasive positive airway pressure ventilation: role in treating acute respiratory failure caused by chronic obstructive pulmonary disease [in Russian]. Anesteziol Reanimatol 1998; 3: 45–51 Barbe R, Togores B, Rubi M, et al. Noninvasive ventilatory support does not facilitate recovery from acute respiratory failure in chronic obstructive pulmonary disease. Eur Respir J 1996; 9: 1240–5 Bott J, Keilty SEJ, Elliott MW, et al. Randomised controlled trial of nasal ventilation in acute ventilatory failure due to chronic obstructive pulmonary disease. Lancet 1993; 341: 1555–7 del Castillo D, Barrot E, Laserna E, et al. Noninvasive positive pressure ventilation for acute respiratory failure in chronic obstructive pulmonary disease in a general respiratory ward [in Spanish]. Medicina Clin (Barc) 2003; 120: 647–51 Dikensoy O, Ikidag B, Filiiz A, et al. Comparison of noninvasive ventilation and standard medical therapy in acute hypercapnic respiratory failure: a randomised controlled trial at a tertiary health centre in SE Turkey. Int J Clin Pract 2002; 56: 85–8 Plant PK, Owen JL, Elliott MW. Early use of non-invasive ventilation for acute exacerbations of chronic obstructive pulmonary disease on general respiratory wards: a multicentre randomised controlled trial. Lancet 2000; 355: 1931–5 Zhou R, Chen P, Luo H, et al. Effects of noninvasive positive pressure ventilation on gas exchange and patients’ transformation in chronic obstructive pulmonary disease and respiratory failure [in Chinese]. Bull Hunan Med Univ 2001; 26: 261–2 Khilnanai GC, Saikia N, Sharma SK, et al. Efficacy of noninvasive positive pressure ventilation (NPPV) for management of COPD with acute or acute on chronic respiratory failure: a randomized controlled trial [abstract]. Am J Respir Crit Care Med 2002; 165 Suppl.: A387 Putinati S, Ballerin L, Piatella M, et al. Is it possible to predict the success of non-invasive ventilation in acute respiratory failure due to COPD? Resp Med 2000; 94: 991–1001 Soo Hoo GW, Santiago S, Williams AJ. Nasal mechanical ventilation for hypercapnic respiratory failure in chronic obstructive pulmonary disease: determinants of success and failure. Crit Care Med 1994; 22: 1253–61 Ambrosino N, Foglio K, Rubini F, et al. Non-invasive mechanical ventilation in acute respiratory failure due to chronic obstructive pulmonary disease: correlates for success. Thorax 1995; 50: 755–7 Mehta S, Hill NS. Noninvasive ventilation. Am J Respir Crit Care Med 2001; 163: 540–77 Behrendt CE. Acute respiratory failure in the United States: incidence and 31-day survival. Chest 2000; 118: 1100–5 Esteban A, Anzueto A, Frutos F, et al. Characteristics and outcomes in adult patients receiving mechanical ventilation: a 28-day international study. JAMA 2002; 287: 345–55 Suissa S. Statistical treatment of exacerbations in therapeutic trials of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2006; 173: 842–6 Scott S, Walker P, Calverley PMA. COPD exacerbations — 4: prevention. Thorax 2006; 61: 440–7 Sin DD, McAlister FA, Man SFP, et al. Contemporary management of chronic obstructive pulmonary disease: scientific review. JAMA 2003; 290: 2301–12 Wilt TJ, Niewoehner D, Kim C, et al. Use of spirometry for case finding, diagnosis, and management of chronic obstructive pulmonary disease (COPD). Evidence report/technology assessment No. 121. Prepared by the Minnesota Evidence-based Practice Center under contract No. 290-02-0009. AHRQ Publication No. 05-E017-2. Rockville (MD). Agency for Healthcare Research and Quality, 2005 Sep [online]. Available from URL: http://www.ahrq.gov/downloads/pub/evidence/pdf/spirocopd/spiro.pdf [Accessed 2007 Feb 28] Anthonisen NR, Connett JE, Kiley JP, et al. Effects of smoking intervention and the use of an inhaled anticholinergic bronchodilator on the rate of decline of FEV1: the Lung Health Study. JAMA 1994; 272: 1497–505 Burchfiel CM, Marcus EB, Curb JD, et al. Effects of smoking and smoking cessation on longitudinal decline in pulmonary function. Am J Respir Crit Care Med 1995; 151: 1778–85 Pelkonen M, Notkola IL, Tukiainen H, et al. Smoking cessation, decline in pulmonary function and total mortality: a 30 year follow up study among the Finnish cohorts of the Seven Countries Study. Thorax 2001; 56: 703–7 Godtfredsen NS, Vestbo J, Osier M, et al. Risk of hospital admission for COPD following smoking cessation and reduction: a Danish population study. Thorax 2002; 57: 967–72 Anthonisen NR, Skeans MA, Wise RA, et al. The effects of a smoking cessation intervention on 14.5-year mortality: a randomized clinical trial. Ann Intern Med 2005; 142: 233–9 Buckland A, Connolly MJ. Age-related differences in smoking cessation advice and support given to patients hospitalised with smoking-related illness. Age Ageing 2005; 34: 639–42 Fiore MC, Bailey WC, Cohen SJ, et al. Treating tobacco use and dependence: clinical practice guideline. Rockville (MD): US Department of Health and Human Services. Public Health Service, 2000 Jun West R, McNeill A, Raw M. Smoking cessation guidelines for health professionals: an update: Health Education Authority. Thorax 2000; 55: 987–99 Anderson JE, Jorenby DE, Scott WJ, et al. Treating tobacco use and dependence: an evidence-based clinical practice guideline for tobacco cessation. Chest 2002; 121: 932–41 Appleton S, Poole P, Smith B, et al. Long-acting beta2-agonists for poorly reversible chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2006; 3: CD001104 Boyd G, Morice AH, Pounsford JC, et al. An evaluation of salmeterol in the treatment of chronic obstructive pulmonary disease (COPD). Eur Respir J 1997; 10: 815–21 Celli B, Halpin D, Hepburn R, et al. Symptoms are an important outcome in chronic obstructive pulmonary disease clinical trials: results of a 3-month comparative study using the Breathlessness, Cough and Sputum Scale (BCSS). Respir Med 2003; 97Suppl. 1: S35–43 Chapman KR, Arvidsson P, Chuchalin AG, et al. The addition of salmeterol 50µg bid to anticholinergic treatment in patients with COPD: a randomized, placebo controlled trial. Can Respir J 2002; 9: 178–85 van Noord JA, de Munck DR, Bantje TA, et al. Long-term treatment of chronic obstructive pulmonary disease with salmeterol and the additive effect of ipratropium. Eur Respir J 2000; 15: 878–85 Barr RG, Bourbeau J, Camargo CA, et al. Tiotropium for stable chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2005; 2: CD002876 Beeh KM, Beier J, Stark-Lorenzen P, et al. Efficacy of tiotropium (Spiriva) in COPD of different severities [abstract] (in German). Pneumologie 2004; 58: S43 Brusasco V, Hodder R, Miravitlles M, et al. Health outcomes following treatment for six months with once daily tiotropium compared with twice daily salmeterol in patients with COPD. Thorax 2003; 58: 399–404 Calverley PMA, Lee A, van Noord J, et al. Effect of tiotropium bromide on circadian variation in airflow limitation in chronic obstructive pulmonary disease. Thorax 2003; 58: 855–60 Casaburi R, Malher DA, Jones PW, et al. A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease. Eur Respir J 2002; 19: 217–24 Celli B, Wallack RZ, Wang S, et al. Improvement in resting inspiratory capacity and hyperinflation with tiotropium in COPD patients with increased static lung volumes. Chest 2003; 124: 1743–8 Littner MR, Ilowite JS, Tashkin DP, et al. Long-acting bronchodilation with once-daily dosing of tiotropium (Spiriva) in stable chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2000; 161: 1136–42 Niewoehner DE, Rice K, Cote C, et al. Prevention of exacerbations of chronic obstructive pulmonary disease with tiotropium, a once-daily inhaled anticholinergic bronchodilator: a randomized trial. Ann Intern Med 2005; 143: 317–26 O’Donnell DE, Fluge T, Gerken F, et al. Effects of tiotropium on lung hyperinflation, dyspnoea, and exercise tolerance in COPD. Eur Respir J 2004; 23: 832–40 Calverley PM. Inhaled corticosteroids are beneficial in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2000; 161: 341–2 Barnes PJ. Inhaled corticosteroids are not beneficial in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2000; 161: 342–4 Alsaeedi A, Sin DD, McAlister FA. The effects of inhaled corticosteroids in chronic obstructive pulmonary disease: a systematic review of randomized placebo-controlled trials. Am J Med 2002; 113: 59–65 Gartlehner G, Hansen RA, Carson SS, et al. Efficacy and safety of inhaled corticosteroids in patients with COPD: a systematic review and meta-analysis of health outcomes. Ann Fam Med 2006; 4: 253–62 Bourbeau J, Rouleau MY, Boucher S. Randomised controlled trial of inhaled corticosteroids in patients with chronic obstructive pulmonary disease. Thorax 1998; 53: 477–82 Burge PS, Calverley PM, Jones PW, et al. Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial. BMJ 2000; 320: 1297–303 Paggiaro PL, Dahle R, Bakran I, et al. Multicentre randomised placebo-controlled trial of inhaled fluticasone propionate in patients with chronic obstructive pulmonary disease: International COPD Study Group. Lancet 1998; 351: 773–80 Vestbo J, Sorensen T, Lange P, et al. Long-term effect of inhaled budesonide in mild and moderate chronic obstructive pulmonary disease: a randomised controlled trial. Lancet 1999; 353: 1819–23 Leech JA, Gervais A, Ruben FL. Efficacy of pneumococcal vaccine in severe chronic obstructive pulmonary disease. CMAJ 1987; 136: 361–5 Franzen D. Clinical efficacy of pneumococcal vaccination: a prospective study in patients with longstanding emphysema and/or bronchitis. Eur J Med Res 2000; 5: 537–40 Nichol KL, Baken L, Wuorenma J, et al. The health and economic benefits associated with pneumococcal vaccination of elderly persons with chronic lung disease. Arch Intern Med 1999; 159: 2437–342 Alfageme I, Vazquez R, Reyes N, et al. Clinical efficacy of antipneumococcal vaccination in patients with COPD. Thorax 2006; 61: 189–95 Centers for Disease Control and Prevention. Prevention of pneumococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 1997; 46(RR-8): 1–24 Howells CHL, Tyler LE. Prophylactic use of influenza vaccine in patients with chronic bronchitis: a pilot trial. Lancet 1961; 2: 1428–32 Wongsurakiat P, Maranetra KN, Wasi C, et al. Acute respiratory illness in patients with COPD and the effectiveness of influenza vaccination: a randomized controlled study. Chest 2004; 125: 2011–20 Nichol KL, Baken L, Nelson A. Relation between influenza vaccination and outpatient visits, hospitalization, and mortality in elderly persons with chronic lung disease. Ann Intern Med 1999; 130: 397–403 Poole PJ, Chacko E, Wood-Baker RW, et al. Influenza vaccine for patients with chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2006; 1: CD002733 Wongsurakiat P, Maranetra KN, Gulprasutdilog P, et al. Adverse effects associated with influenza vaccination in patients with COPD: a randomized controlled study. Respirology 2004; 9: 550–6 Tata LJ, West J, Harrison T, et al. Does influenza vaccination increase consultations, corticosteroid prescriptions, or exacerbations in subjects with asthma or chronic obstructive pulmonary disease? Thorax 2003; 58: 835–9 Poole PJ, Black PN. Mucolytic agents for chronic bronchitis or chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2006; 3: CD001287 Decramer M, Rutten-van Molken M, Dekhuijzen PN, et al. Effects of N-acetylcysteine on outcomes in chronic obstructive pulmonary disease (Bronchitis Randomized on NAC Cost-Utility Study, BRONCUS): a randomised placebo-controlled trial. Lancet 2005; 365: 1552–60 Foglio K, Bianchi L, Bruletti G, et al. Long-term effectiveness of pulmonary rehabilitation in patients with chronic airway obstruction. Eur Respir J 1999; 13: 125–32 Griffiths TL, Burr ML, Campbell IA, et al. Results at 1 year of outpatient multidisciplinary pulmonary rehabilitation: a randomised controlled trial. Lancet 2000; 355: 362–8 Guell R, Casan P, Belda J, et al. Long-term effects of outpatient rehabilitation of COPD: a randomized trial. Chest 2000; 117: 976–83 Foglio K, Bianchi L, Ambrosino N. Is it really useful to repeat outpatient pulmonary rehabilitation programs in patients with chronic airway obstruction? A 2-year controlled study. Chest 2001; 119: 1696–704 Taylor SJ, Candy B, Bryar RM, et al. Effectiveness of innovations in nurse led chronic disease management for patients with chronic obstructive pulmonary disease: systematic review of evidence. BMJ 2005; 331: 485–91 Bourbeau J, Julien M, Maltais F, et al. Reduction of hospital utilization in patients with chronic obstructive pulmonary disease: a disease-specific self-management intervention. Arch Intern Med 2003; 163: 585–91 Casas A, Troosters T, Garcia-Aymerich J, et al. Integrated care prevents hospitalizations for exacerbations in COPD patients. Eur Respir J 2006; 28: 123–30